Pharma BD Deal Intelligence

Bristol-Myers Squibb Company / Five Prime Therapeutics, Inc. (CSF1R antibody program)

2015 · Licensing/Option · $1.7B · Terminated

Announcement Sentiment

Negative

BMS entered an exclusive worldwide license and collaboration with Five Prime for the CSF1R antibody program including FPA008 (cabiralizumab). Five Prime received $350M upfront with up to $1.39B in development and regulatory milestones plus tiered double-digit royalties. The pivotal Opdivo + cabiralizumab pancreatic cancer trial (CARRY) failed in 2020.

Key facts

Announced Oct 14, 2015
Closed Nov 23, 2015
Deal value $1.7B
Deal type Licensing/Option
Therapeutic area Pigmented villonodular synovitis (PVNS); solid tumors in combination with Opdivo
Indications Pigmented villonodular synovitis (PVNS); solid tumors in combination with Opdivo
Key assets Cabiralizumab (FPA008)
Mechanism Anti-colony stimulating factor 1 receptor (CSF1R) monoclonal antibody (tumor-associated macrophage modulator)

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals